OPKO Health Forecasts 30% 2026 Growth as Q3 RAYALDEE Revenues Hit $7.5M
OPKO Health’s RAYALDEE generated net product revenues of $7.5 million in Q3 and $21.0 million in the nine months ended September 30, 2025, while shares have declined 10.3% over six months versus a 7.8% industry drop. The company forecasts 30% fiscal 2026 growth supported by pipeline collaborations on LA-PTH and multispecific antibodies.
1. RAYALDEE Commercial Performance
OPKO Health’s flagship product RAYALDEE recorded net revenues of $7.5 million in Q3 and $21.0 million for the nine months ended September 30, 2025. Despite broad distribution and rebate agreements, the stock has underperformed, falling 10.3% over six months compared with a 7.8% industry decline.
2. Strategic Collaborations
In early 2025, OPKO Biologics and Entera Bio expanded their collaboration on an oral long‐acting PTH analog (LA-PTH) for hypoparathyroidism. ModeX Therapeutics licensed its MSTAR platform to Regeneron for multispecific antibody development, and OPKO completed the sale of select BioReference Health assets to streamline diagnostics operations.
3. Clinical Pipeline Updates
ModeX’s MDX2004 trispecific antibody entered Phase 1/2a with first patient dosing, while the tetraspecific T-cell engager MDX2001 reached its fifth dose level, with Phase 1b studies planned. The EBV vaccine program advanced into Phase 1 trials and an oral GLP-2 treatment for short bowel syndrome presented promising pharmacokinetics.
4. Financial Outlook and Risks
OPKO projects 30% top-line growth in fiscal 2026, with first-quarter revenues estimated at $130.9 million and an improved loss per share. However, overreliance on RAYALDEE exposes the company to reimbursement challenges, pricing pressure and potential formulary constraints that could hinder overall performance.